19:25 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

ADORA2A identified as a thrombosis target

DISEASE CATEGORY: Cardiovascular INDICATION: Thrombosis Cell culture and mouse studies suggest agonizing ADORA2A could help treat thrombosis. In primary human and mouse neutrophils treated with IgG from patients with antiphospholipid syndrome (APS), which is associated...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Glycosphingolipid storage disorders Adenosine A2A receptor (ADORA2A) In vitro studies suggest ADORA2A agonists could help treat Niemann-Pick disease type C1...
07:00 , Aug 30, 2012 |  BC Innovations  |  Cover Story

Dissociating the effects of A2A agonism

The vasodilatory effects of adenosine A2A receptor agonists make them useful as cardiac stress agents in imaging but have made it difficult to exploit these molecules' potent anti-inflammatory effects. 1 Researchers in Germany have dissociated...
07:00 , Jun 21, 2012 |  BC Innovations  |  Targets & Mechanisms

ADORAble implants

Researchers at the New York University Langone Medical Center have found a way to ward off a leading cause of joint implant failure. 1 The group has shown that adenosine A2A receptor agonists can block...
07:00 , Mar 26, 2012 |  BC Week In Review  |  Clinical News

BVT: Completed Phase II enrollment

CRO Ergomed completed enrollment of 120 patients in a Phase II trial evaluating oral BVT.115959. CBT Development, a virtual company between venture investors Avlar BioVentures and Excalibur Fund Managers, partnered with Ergomed last year to...
07:00 , May 23, 2011 |  BC Week In Review  |  Company News

Ergomed Group deal

CBT Development Ltd. , a virtual company between venture investors Avlar BioVentures Ltd. (Cambridge, U.K.) and Excalibur Fund Managers Ltd. (Cambridge, U.K.), and CRO Ergomed partnered to co-develop CBT's neuropathic pain candidate BVT.115959 . The...